Quarterly ResultMay 12, 2026, 07:02 PM
Anteris Q1 Net Operating Cash Outflows $28.7M; Raises $320M
AI Summary
Anteris Technologies Global Corp. reported Q1 2026 financial results, including net operating cash outflows of $28.7 million, primarily due to clinical, regulatory, and manufacturing requirements for the PARADIGM Trial. The company successfully completed aggregate capital raises totaling $320 million in January 2026 to support the trial and advance toward global commercialization of the DurAVR THV System. Significant progress was made in the PARADIGM Trial, with patient enrollment ongoing in Europe and commencing in the U.S. post-quarter end, supported by CMS coverage determination.
Key Highlights
- Completed aggregate capital raises totaling $320 million in January 2026.
- Reported net operating cash outflows of $28.7 million for Q1 2026.
- R&D expenses reached $17.5 million, driven by manufacturing and PARADIGM Trial activities.
- PARADIGM Trial patient enrollment commenced in the U.S. post-quarter end.
- CMS coverage determination is expected to facilitate U.S. patient recruitment for the trial.
- The PARADIGM Trial aims to enroll approximately 1,000 patients.
- ADAPT tissue has been used clinically for over 10 years in over 55,000 patients.
Price Impact
More from AVR